Form 4: Design Therapeutics CEO Granted 750,000 Stock Options

Design Therapeutics, Inc. President, CEO, and Chairperson Pratik Shah was granted 750,000 stock options with a $9.1 exercise price.

Summary

• Pratik Shah, President, CEO, and Chairperson of Design Therapeutics, Inc. (DSGN), was granted 750,000 stock options.
• The options have an exercise price of $9.1 per share.
• The earliest transaction date for this grant was January 2, 2026.
• The options will vest over approximately four years: 20% on January 1, 2027, followed by 20% in equal monthly installments over the subsequent 12 months, then 30% in equal monthly installments over the next 12 months, and finally 30% in equal monthly installments over the final 12 months.
• The options are exercisable and expire on January 1, 2036.
• Following this transaction, Pratik Shah beneficially owns 750,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is generally viewed as a positive for aligning management incentives with shareholder interests, indicating confidence in future growth. However, it is a compensation event rather than a direct indicator of immediate financial performance.

Positives

• The grant of stock options to the President, CEO, and Chairperson aligns management's long-term interests with those of shareholders, incentivizing performance and value creation.
• Equity compensation is a standard practice to attract and retain top executive talent.

Negatives

• The future exercise of these options could lead to dilution for existing shareholders, although this is a common aspect of equity compensation plans.

Risks

• The value of the stock options is directly tied to the future performance of Design Therapeutics' common stock, meaning the options may not become 'in-the-money' if the stock price does not rise above the exercise price of $9.1.
• Market volatility and company-specific operational risks could negatively impact the stock price, reducing the potential value of these options.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's financial performance or strategic outlook.

Industry Context

Executive equity compensation, such as stock option grants, is a standard practice across the biotechnology and pharmaceutical industries to incentivize leadership and align their financial interests with long-term company success and shareholder value.

Comparison to Industry Standards

• The grant of 750,000 stock options to a CEO of a publicly traded biotechnology company is within the typical range for executive compensation packages, which often include a significant equity component to motivate long-term performance.
• The four-year vesting schedule with a one-year cliff is a common structure designed to retain executives and ensure sustained commitment to company goals, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their executive teams.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through incentivized management, but also potential for future share dilution upon option exercise.
• Management (Pratik Shah): Significant financial incentive tied to the company's stock performance, enhancing motivation and retention.

Next Steps

• The options will vest according to the specified schedule, with the first tranche vesting on January 1, 2027.
• Pratik Shah may exercise these options at any time after they vest and before their expiration date of January 1, 2036, assuming the stock price is above the exercise price.

Key Dates

Keywords

Design Therapeutics, DSGN, Pratik Shah, stock options, executive compensation, insider transaction, equity grant, vesting